Medical management of mild to moderate Crohn's disease: evidence-based treatment algorithms for induction and maintenance of remission.
about
Chronic inflammation up-regulates P-gp in peripheral mononuclear blood cells via the STAT3/Nf-κb pathway in 2,4,6-trinitrobenzene sulfonic acid-induced colitis miceNonsteroidal anti-inflammatory medications are cytostatic against human vestibular schwannomas.Stem cells as potential therapeutic targets for inflammatory bowel disease.Inflammatory bowel disease: clinical aspects and treatments.Behavioral interventions may prolong remission in patients with inflammatory bowel disease.Optimizing management of Crohn's disease within a project management framework: results of a pilot study.Are patients with inflammatory bowel disease on chronic immunosuppressive therapy at increased risk of cervical high-grade dysplasia/cancer? A meta-analysis.Variation in Antibiotic Use for Children Hospitalized With Inflammatory Bowel Disease Exacerbation: A Multicenter Validation Study.Predicting drug-target interactions using restricted Boltzmann machines.JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokinesControversies in the treatment of Crohn's disease: the case for an accelerated step-up treatment approachLooking for the best anti-colitis medicine: A comparative analysis of current and prospective compounds.Clinical scenarios in IBD: optimizing the use of conventional and biologic agents.Recent advances in understanding Crohn's disease.Steroid use in Crohn's disease.Approach to the Patient with Mild Crohn's Disease: a 2016 Update.Anti-Inflammatory Effects of Hyperbaric Oxygenation during DSS-Induced Colitis in BALB/c Mice Include Changes in Gene Expression of HIF-1α, Proinflammatory Cytokines, and Antioxidative Enzymes.Predicting Outcomes and Tailoring Therapy in the Diagnosis and Treatment of IBD.Response to medical treatment in patients with Crohn's disease: the role of NOD2/CRAD15, disease phenotype, and age of diagnosis.Prevention of postoperative recurrence of Crohn's disease: Tripterygium wilfordii polyglycoside versus mesalazine.Granulomatous appendicitis in a child.Vedolizumab Therapy Is Associated with an Improvement in Sleep Quality and Mood in Inflammatory Bowel Diseases.Oral administration of non-absorbable delayed release 6-mercaptopurine is locally active in the gut, exerts a systemic immune effect and alleviates Crohn's disease with low rate of side effects: results of double blind Phase II clinical trial.Supramolecular interaction of 18-crown-6 ether with mesalazine and spectrofluorimetric determination of mesalazine in pharmaceutical formulations.Comparison of Concomitant Mesalamine and Immunomodulator Therapy and Immunomodulator Monotherapy for Crohn's Disease.
P2860
Q28608251-B343A6B7-4C16-42A8-A66D-E05270F6DBD7Q30380561-19EFF652-032B-4E66-8003-406F6A60798BQ33975300-D4E5BD97-65FA-4163-AE11-6833614F8B7AQ34431476-A50614BB-5D8E-496A-A6EC-F695DBBEE870Q34590491-532E7377-AB9F-45D2-8140-D5F3D133C4AEQ35036687-5AC11422-6B54-4DB0-B61E-D28E50DFF444Q35690978-C45923E6-AC2C-4721-9375-DEBEF8C26C39Q36851121-DFEF8DAE-92D0-4810-8261-215EBC0BA4FDQ36960730-039A4C1A-2220-4D0E-A7DC-4A73717304EBQ37148745-914A8339-6BE1-4A0B-8D7D-A66B48FD0F6FQ37156633-4CE9839E-EF9C-4F6A-87F2-75FF12D3A31FQ37702204-F20DC2FB-0CA4-4BDA-BDB2-AB228CD1DEB3Q37812046-06C3B842-E20F-4E40-8AEC-FA2248539B67Q37873392-AF5BA906-B595-413E-9DAD-9FE05674E949Q38188477-077B7E9D-7748-41DE-973B-1FEF1DCF5863Q38905783-038F670E-4C5F-4D04-87E8-998CA5CB7428Q41080205-21C068F9-019B-4F63-9F6A-FAACA28F3374Q42233323-489A71B3-4CF0-431C-9F7D-92A0CA0B8703Q43289269-ED8411EC-96E8-47B2-9083-73E03E123AD5Q45909147-4C94CC7F-2D3A-49DE-B2A6-735921B2557FQ46975399-A1DFBC61-68C0-4A47-8619-8053A061F8F6Q47095956-3746EAB1-5723-412A-A737-64A1F6E248D7Q53556158-AE736F64-7F0A-437F-B990-41B7F495D10CQ53805302-34698717-4A18-4DCD-A383-1E57B67DE736Q55162386-BC116877-9B01-45F7-B075-5EDD8008B620
P2860
Medical management of mild to moderate Crohn's disease: evidence-based treatment algorithms for induction and maintenance of remission.
description
2007 nî lūn-bûn
@nan
2007 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Medical management of mild to ...... and maintenance of remission.
@ast
Medical management of mild to ...... and maintenance of remission.
@en
Medical management of mild to ...... and maintenance of remission.
@nl
type
label
Medical management of mild to ...... and maintenance of remission.
@ast
Medical management of mild to ...... and maintenance of remission.
@en
Medical management of mild to ...... and maintenance of remission.
@nl
prefLabel
Medical management of mild to ...... and maintenance of remission.
@ast
Medical management of mild to ...... and maintenance of remission.
@en
Medical management of mild to ...... and maintenance of remission.
@nl
P1476
Medical management of mild to ...... and maintenance of remission.
@en
P2093
Lichtenstein GR
Sandborn WJ
P304
P356
10.1111/J.1365-2036.2007.03455.X
P407
P577
2007-10-01T00:00:00Z